Table 1.
Comment | Reference | |
---|---|---|
HLA antibody | ||
Concentration | Not currently possible to measure antigen-specific concentration of antibody (see Figure 3) | |
Antibody binding to HLA in solid phase assay (readout a combination of avidity and concentration) | Measureable by microbead assays | [2, 4] |
Class | Mostly IgG, early reports of IgM mediated AMR and occurrence of IgA | [20, 21] |
Subclass | Early studies show heterogeneity in responses | [21, 22] |
Affinity | Measurement under investigation | |
Glycosylation | Measurement under investigation | |
Cellular binding | CDC and FC crossmatches Endothelial binding |
[2, 23] |
Inhibitors | ||
Soluble HLA | Early reports of methods to quantify | |
HLA-E | Early reports of correlation with clinical outcomes | [24] |
Idiotypic antibodies | Hard to measure with current tools but could be important | [25] |
Immune complexes | ||
HLA-sHLA immune complexes | Not currently measureable |